Ensign Peak Advisors, Inc Apellis Pharmaceuticals, Inc. Transaction History

Ensign Peak Advisors, Inc

$56.1 Billion
Q3 2024

A detailed history of Ensign Peak Advisors, Inc transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 80,997 shares of APLS stock, worth $2.68 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

80,997

Previous 82,997 2.41%

Holding current value

$2.68 Million

Previous $3.18 Million 26.64%

% of portfolio

0.0%

Previous 0.01%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$28.84 - $41.15 $57,680 - $82,300	-2,000 Reduced 2.41%	80,997 $2.34 Million
Q2 2024 Aug 13, 2024	SELL	$38.07 - $59.71 $6.75 Million - $10.6 Million	-177,277 Reduced 68.11%	82,997 $3.18 Million
Q1 2024 May 14, 2024	BUY	$55.39 - $72.47 $814,676 - $1.07 Million	14,708 Added 5.99%	260,274 $15.3 Million
Q4 2023 Feb 14, 2024	BUY	$37.14 - $64.82 $2.23 Million - $3.89 Million	60,000 Added 32.33%	245,566 $14.7 Million
Q3 2023 Nov 13, 2023	BUY	$23.65 - $89.22 $3.66 Million - $13.8 Million	154,686 Added 500.93%	185,566 $7.06 Million
Q2 2023 Aug 14, 2023	BUY	$76.68 - $93.31 $72,846 - $88,644	950 Added 3.17%	30,880 $2.81 Million
Q1 2023 May 15, 2023	SELL	$46.59 - $66.96 $6.22 Million - $8.94 Million	-133,500 Reduced 81.69%	29,930 $1.97 Million
Q4 2022 Feb 13, 2023	BUY	$43.24 - $61.04 $6.1 Million - $8.61 Million	141,100 Added 631.89%	163,430 $8.45 Million
Q3 2022 Nov 14, 2022	SELL	$44.76 - $69.66 $5.27 Million - $8.21 Million	-117,829 Reduced 84.07%	22,330 $1.53 Million
Q2 2022 Aug 12, 2022	BUY	$35.07 - $59.21 $3.51 Million - $5.92 Million	99,979 Added 248.83%	140,159 $6.34 Million
Q1 2022 May 16, 2022	SELL	$35.46 - $54.12 $1.61 Million - $2.46 Million	-45,409 Reduced 53.05%	40,180 $2.04 Million
Q4 2021 Feb 11, 2022	BUY	$30.74 - $49.16 $2.54 Million - $4.06 Million	82,647 Added 2809.21%	85,589 $4.05 Million
Q3 2021 Nov 12, 2021	SELL	$31.4 - $69.84 $1.38 Million - $3.06 Million	-43,821 Reduced 93.71%	2,942 $97,000
Q2 2021 Aug 13, 2021	BUY	$40.9 - $64.9 $166,135 - $263,623	4,062 Added 9.51%	46,763 $2.96 Million
Q4 2020 Feb 12, 2021	BUY	$30.79 - $57.2 $235,728 - $437,923	7,656 Added 21.85%	42,701 $2.44 Million
Q3 2020 Nov 12, 2020	BUY	$25.89 - $33.65 $271,715 - $353,156	10,495 Added 42.75%	35,045 $1.06 Million
Q2 2020 Aug 12, 2020	BUY	$24.8 - $38.49 $418,004 - $648,748	16,855 Added 219.04%	24,550 $802,000
Q1 2020 May 11, 2020	SELL	$17.91 - $44.33 $45,366 - $112,287	-2,533 Reduced 24.77%	7,695 $206,000
Q4 2019 Feb 14, 2020	BUY	$22.1 - $30.8 $226,038 - $315,022	10,228 New	10,228 $314,000

Others Institutions Holding APLS

# of Institutions

308

Shares Held

115M

Call Options Held

3.85M

Put Options Held

1.09M

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.

Account

Ensign Peak Advisors, Inc Apellis Pharmaceuticals, Inc. Transaction History